Pharmacological therapies with incretin-based ‘multi-agonists’ are rapidly advancing the therapeutic landscape for obesity. The loss of skeletal muscle mass with these potent weight-loss agents is emerging as a possible side effect. It is therefore important to determine whether multi-agonists increase the risk of sarcopenia in susceptible patients.

中文翻译：

---

肥胖药物治疗中的骨骼肌损失和肌肉减少症


基于肠促胰素的“多激动剂”的药物疗法正在迅速推进肥胖症的治疗前景。这些有效的减肥剂可能会导致骨骼肌质量下降，从而产生副作用。因此，确定多激动剂是否会增加易感患者患肌少症的风险非常重要。